Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAFAMIDIS MEGLUMINE for Polyneuropathy: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where TAFAMIDIS MEGLUMINE was used for Polyneuropathy.

Most Reported Side Effects for TAFAMIDIS MEGLUMINE

Side Effect Reports % Deaths Hosp.
Death 1,196 27.2% 1,183 70
Cardiac failure 519 11.8% 166 314
Off label use 418 9.5% 129 100
Dyspnoea 227 5.2% 22 92
Product use in unapproved indication 202 4.6% 62 49
Cardiac failure chronic 188 4.3% 68 28
Atrial fibrillation 164 3.7% 21 87
Fatigue 163 3.7% 16 45
Disease progression 157 3.6% 68 35
Condition aggravated 144 3.3% 35 69
Asthenia 125 2.8% 29 57
Fall 120 2.7% 32 92
Dizziness 116 2.6% 15 35
Diarrhoea 94 2.1% 13 34
Weight decreased 90 2.0% 9 31

Other Indications for TAFAMIDIS MEGLUMINE

Cardiac amyloidosis (2,027) Amyloidosis (641) Hereditary neuropathic amyloidosis (252) Amyloidosis senile (143) Cardiomyopathy (102) Familial amyloidosis (95) Product used for unknown indication (67) Acquired attr amyloidosis (66) Cardiac disorder (47) Cardiac failure congestive (24)

Other Drugs Used for Polyneuropathy

PREGABALIN (884) HUMAN IMMUNOGLOBULIN G (529) GABAPENTIN (180) INOTERSEN (62) RITUXIMAB (56) DULOXETINE (45) LENALIDOMIDE (42) PATISIRAN (36) EPLONTERSEN (21) CLONAZEPAM (17)

Related Pages

TAFAMIDIS MEGLUMINE Full Profile All Polyneuropathy Drugs TAFAMIDIS MEGLUMINE Demographics TAFAMIDIS MEGLUMINE Timeline